CDMO Education Centre

close
08 Aug 2024

Advancing Allogeneic CAR T Cell Therapies: Overcoming Challenges in Workflow and Manufacturing

Autologous chimeric antigen receptor (CAR) T cell therapies have shown...

27 May 2024

Understanding Reprogramming of Induced Pluripotent Stem Cells, and Considerations for Use in GMP Manufacturing

It was less than 20 years ago that the foundational study by Takahashi...

09 Apr 2024

The Vital Role of Process Closure and Automation in CAR T Manufacturing

Chimeric antigen receptor (CAR)-based T cell immune therapies are now ...

08 Mar 2024

Finding Your Goldilocks: Choosing the Ideal Cell and Gene Therapy CDMO

In the evolving cell and gene therapy market, when it comes to selecti...

13 Feb 2024

Developing an Analytical Development Strategy for Immunotherapy

Cell and gene therapies are groundbreaking approaches to medicine, off...

08 Dec 2022

The 3 Best Ways to Manufacture and Scale Up Lentiviral Vectors

LVVs are essential in the manufacture of cellular immunotherapies (e.g...

08 Dec 2022

Upstream and Downstream Considerations for Scaling Up Lentiviral Vector Production

Lentiviral vectors (LVVs) are often used to deliver genetic material f...

18 Aug 2022

Top 6 Tips to Speed Up Manufacturing Your CGT Product

Managing the manufacturing process for cell and gene therapy (CGT) pro...

13 Apr 2022

The Canadian Regulatory System for Cell and Gene Therapies

Regenerative medicine is bringing about an entirely novel therapeutic ...

Tell us what you thought about this post.